Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101's Promise in IGF-1R Prominent Cancers
The first presentation, co-authored with investigators from the MD Anderson Cancer Center, showcases LX-101's strong in vivo activity in Ewing sarcoma as well as its potency in in vitro models of both Ewing sarcoma and desmoplastic small round cell tumor (DSRCT). These cancers have strong ties to IGF-1R, including DNA-level gene fusions that affect this signaling pathway. The second presentation highlights LX-101's broad potency against a host of IGF-1R-expressing cell lines from a number of additional adult cancers including lung, esophageal and stomach cancers, which represent large market opportunities. These presentations underscore LX-101's potent activity and promise in both pediatric and adult cancers with well-established ties to the IGF-1R pathway.
The presentations are entitled:
LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal Models and Desmoplastic Small Round Cell Tumors.
LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Elevated IGF-1R Expression.
Both presentations are available on the Lirum website ( www.lirumtx.com) under the Investors and Media tab.
Given these promising results, new clinical trials with LX-101 are planned in pediatric indications that carry strong ties to the IGF-1/IGF-1R pathway, including Ewing Sarcoma, DSRCT, rhabdomyosarcoma, and GIST. In addition, Lirum is planning trials in adult patients with cancer types that are naturally enriched for IGF-1R, including certain head and neck indications and others. In parallel, Lirum is also focused on developing LX-101 in thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated.
About Lirum Therapeutics, Inc.
Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum's lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit www.lirumtx.com.
Forward Looking Statements
This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Lirum's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the ability of Lirum to successfully develop its product candidates, including obtaining positive results from planned clinical trials, 2) expectations for the clinical development, manufacturing, regulatory approval and commercialization of our product candidates or other products we may acquire or in-license(3) expectations for incurring capital expenditures and generating revenue, 4) estimates of the sufficiency of our existing cash and cash equivalents and investments to finance operations, 5) changes in applicable laws or regulations; (6) the possibility that Lirum may be adversely affected by other economic, business, and/or competitive factors; (7) the impact of health epidemics, including the COVID-19 pandemic, on Lirum's business and the actions Lirum may take in response thereto; and (8) other risks and uncertainties indicated from time to time. There may be additional risks that Lirum considers immaterial or which are unknown. Any forward-looking statement made by us in this press release is based only on information currently available to Lirum and speaks only as of the date on which it is made. Lirum undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. Also, the information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Company contact:
Matt Hoberman
Lirum Therapeutics, Inc.
1270 Ave of the Americas, 7th Floor
New York, NY 10020
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Japan Ministry of Defense's Air Self-Defense Force Powers Cloud Content Management with Box
TOKYO--(BUSINESS WIRE)--Box, Inc. (NYSE: BOX), the leading Intelligent Content Management (ICM) platform, today announced that the Japan Ministry of Defense's Air Self-Defense Force (ASDF) has selected and is deploying Box to power secure cloud content management and collaboration across its operations. With Box, ASDF can securely share information both internally and externally with affiliated agencies and partners, enabling close knowledge sharing between units. The ASDF plays a critical role in national defense by maintaining airspace security and supporting disaster relief efforts throughout Japan. In addition, the ASDF has an urgent need to digitize and automate its operations, and to integrate and streamline its information systems to counter recent sophisticated cyber-attacks, human resource constraints and the rapidly changing security environment. Until now, on-premise file servers were installed at each of the 73 bases across the country, but while stored securely, these servers faced capacity issues, created management and other workload burdens, and placed barriers to collaboration and access to content. With the introduction of Box, the entire 47,000-plus workforce will improve productivity and operational efficiency in a state-of-the-art digital environment, all with enhanced security and capacity. Key use cases with Boxes include: A secure collaboration environment for the vast amount of information and documents handled by the ASDF Improved business efficiency and security through extensive integration Detailed access rights control and trail management of various logs (activity logs, audit logs, etc.) Centralized content management (including advanced administrative document management) 'As government agencies are considering cloud services (e.g. SaaS) as their first choice in accordance with the cloud-by-default principle to improve organizational capabilities, public service and safety, the Ministry of Defense, Air Self-Defense Force is also enhancing its mission capability with Box's intelligent content management platform,' says Noriyuki Sato, President at Box Japan. 'We will continue to support the powerful combination of content plus AI built into Box, and contribute to the digital transformation of our customers in Japan as the leading platform for protecting enterprise content.' Box is FedRAMP High certified and registered with the Security Rating System for Government Information Systems (ISMAP) in Japan, and its reliability has been proven by government organizations around the world, including NASA and the US Air Force. About Box Box (NYSE:BOX) is the leader in Intelligent Content Management. Our platform enables organizations to fuel collaboration, manage the entire content lifecycle, secure critical content, and transform business workflows with enterprise AI. Founded in 2005, Box simplifies work for leading global organizations, including AstraZeneca, JLL, Morgan Stanley, and Nationwide. Box is headquartered in Redwood City, CA, with offices across the United States, Europe, and Asia. Visit to learn more. And visit to learn more about how Box empowers nonprofits to fulfill their missions.
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
Cloudflare: Q2 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Cloudflare, Inc. (NET) on Thursday reported a loss of $50.4 million in its second quarter. The San Francisco-based company said it had a loss of 15 cents per share. Earnings, adjusted for one-time gains and costs, came to 21 cents per share. The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of 18 cents per share. The web security and content delivery company posted revenue of $512.3 million in the period, also topping Street forecasts. Eleven analysts surveyed by Zacks expected $500.7 million. The company said it expects revenue in the range of $543.5 million to $544.5 million for the fiscal third quarter. Cloudflare expects full-year earnings in the range of 85 cents to 86 cents per share, with revenue ranging from $2.11 billion to $2.12 billion.
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Perseus Mining announces retirement of CEO and appointment of new CEO
Perth, Aug. 01, 2025 (GLOBE NEWSWIRE) — perseus mining MANAGING DIRECTOR announces retirement; new MD & CEO appointed SUMMARY Perseus Mining Limited (ASX/TSX:PRU) announces its long-serving Managing Director and Chief Executive Officer (MD and CEO) Jeff Quartermaine has advised he will retire from the role of Perseus's MD and CEO after serving for 12 years. His retirement will take effect from September 30, 2025, after which he has agreed to continue to support the Company through a Consultancy Agreement on market terms. Mr. Quartermaine joined Perseus in 2010 as Chief Financial Officer, before being appointed CEO in 2013. Since assuming this role, he has transformed Perseus from a struggling single-mine, single-country company to a multi-mine, multi-jurisdictional gold producer, developer and explorer that has consistently delivered on its promises and is now one of the leading gold companies operating on the African continent. Perseus now has three operating gold mines, Edikan in Ghana and Yaouré and Sissingué in Côte d'Ivoire, and is building a fourth mine, Nyanzaga, in Tanzania, which is on track to commence gold production in Q1 CY2027. Perseus's Chairman Rick Menell praised Mr Quartermaine's outstanding contribution in leading and shaping Perseus into the company it is today, saying: ' On behalf of the Board, I would like to express my most sincere gratitude to Jeff for his leadership and guidance over the years. Jeff has transformed Perseus and has been pivotal in turning it into one of the most profitable gold producers in the world. He has built extremely solid foundations for the Company to keep growing and we cannot thank him enough for such a positive legacy .' Outgoing MD and CEO, Mr. Quartermaine said: 'It has been an honour and a privilege to have had the opportunity to serve at the helm of Perseus Mining over the past 12 years. Not only has the Company been transformed into a credible ASX 100 organisation, but during this time we have generated significant benefits for all of our stakeholders, including many in our host communities in Africa whose lives have been significantly improved through Perseus's endeavours. I am deeply indebted to all our staff, both past and present, who along with their families have given their friendship, hard work, and commitment in helping transform Perseus. Along the way we have faced a myriad of challenges including events such as the global COVID pandemic, but we have emerged stronger than ever, and the company is now well positioned to continue our success into the future. In reflecting on the last 15 years at Perseus, I must acknowledge the enormous contribution made to my career and indirectly to the success of Perseus, by my own family whose unwavering support has made the journey so much easier.' Mr. Quartermaine will be replaced as MD and CEO by Craig Jones, who will commence work with Perseus on August 18, 2025 and will assume the positions of MD and CEO with effect from October 1, 2025. Mr Jones joins Perseus with more than 25 years of global experience, having worked across Australia, Papua New Guinea (PNG), Indonesia and Canada. He was a member of Newcrest's executive team from 2012, having originally joined in 2008, and ultimately serving as Newcrest's global COO, with broad responsibility for five operating assets spread across multiple jurisdictions. In that capacity, he played a critical role in the development of organisational strategies, due diligence and investor relations. Mr Jones also led high-level engagement with governments, communities and First Nations groups across PNG, Canada and Australia. Beyond his executive roles, Mr. Jones was a Newcrest nominee director on the Boards of SolGold and Lundin Gold and was Newcrest's representative on Joint Venture Committees including the Morobe Mining Joint Venture in PNG and the Red Chris Joint Venture in British Columbia, reflecting extensive global resource-sector connectivity and governance experience. A values-driven leader recognised for enhancing safety and fostering a strong organisational culture, Mr Jones is known for his consistent, empathetic and principled leadership style, which has earned the respect of peers, governments and communities alike. Mr Menell said: 'We are delighted to welcome Craig to the Perseus team as Managing Director and CEO. Perseus is going through a significant phase of growth, in an environment that is getting increasingly complex, so we need a leader of Craig's calibre to build on Jeff's incredible legacy and confirm – and further grow – our position as one of the world's better performing mid-tier gold producers. Craig brings a wealth of strategic, operational and technical expertise, a deep understanding of complex operating jurisdictions and stakeholder management and a clear commitment to sustainable practices. We look forward to working with Craig and the rest of the Perseus team to bring the Company even further.' Mr. Jones will be based in Perseus's head office in Perth, Western Australia. A summary of the material terms of the employment agreement between Perseus and Mr. Jones is provided in Appendix A of this announcement. Appendix A: CEO Summary of Key Terms of employment This market announcement was authorised for release by the Chairman of the Board of Perseus Mining Limited, Rick Menell.
